Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BPL003
MIFTS: 61

Bipolar Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bipolar Disorder

About this section

MalaCards integrated aliases for Bipolar Disorder:

Name: Bipolar Disorder 39 12 77 54 26 38 56 44 45 15 17 74
Major Affective Disorder 54 41 74
Bipolar Affective Disorder 54 26
Depression, Bipolar 26 74
Bipolar Depression 12 15
Manic Depression 12 54
Manic Disorder 12 74
Manic Bipolar Affective Disorder 12
Bipolar Disorder Manic Phase 12
Bipolar Affective Psychosis 26
Major Affective Disorder 1 74
Manic-Depressive Psychosis 54
Major Affective Disorder 2 74
Manic Depressive Disorder 12
Bipolar Spectrum Disorder 26
Manic Bipolar I Disorder 12
Manic Depressive Illness 26
Affective Disorder Major 56
Depressive-Manic Psych. 12
Bipolar Disorder, Mixed 74
Mixed Bipolar Disorder 12
Depression Bipolar 56
Bipolar Illness 54

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34


Sources

Summaries for Bipolar Disorder

About this section
MedlinePlus : 44 Bipolar disorder is a serious mental illness. People who have it go through unusual mood changes. They go from very happy, "up," and active to very sad and hopeless, "down," and inactive, and then back again. They often have normal moods in between. The up feeling is called mania. The down feeling is depression. The causes of bipolar disorder aren't always clear. It runs in families. Abnormal brain structure and function may also play a role. Bipolar disorder often starts in a person's late teen or early adult years. But children and adults can have bipolar disorder too. The illness usually lasts a lifetime. If you think you may have it, tell your health care provider. A medical checkup can rule out other illnesses that might cause your mood changes. If not treated, bipolar disorder can lead to damaged relationships, poor job or school performance, and even suicide. However, there are effective treatments to control symptoms: medicine and talk therapy. A combination usually works best. NIH: National Institute of Mental Health

MalaCards based summary : Bipolar Disorder, also known as major affective disorder, is related to major depressive disorder and bipolar i disorder. An important gene associated with Bipolar Disorder is DAOA-AS1 (DAOA Antisense RNA 1), and among its related pathways/superpathways is Neurotransmitter Clearance In The Synaptic Cleft. The drugs Risperidone and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A mood disorder that involves alternating periods of mania and depression.

Genetics Home Reference : 26 Bipolar disorder is a mental health condition that causes extreme shifts in mood, energy, and behavior. This disorder most often appears in late adolescence or early adulthood, although symptoms can begin at any time of life.

NIH Rare Diseases : 54 Bipolar disorder is a type of mental illness that causes unusual shifts in mood, energy, activity levels, sleep and behavior. Signs and symptoms typically include alternating periods of manic episodes (joyful or excited states) and depressive episodes (very sad, hopeless or empty states). Mood episodes may also include symptoms of both mania and depression (a mixed state). It often develops in the late teens or early adult years, but age of onset can range from childhood to late in life. Bipolar disorder can run in families, although no single gene is thought to cause the condition. Many factors acting together likely increase a person's risk to develop the disorder. Treatment may include medication and psychotherapy for preventing relapses and reducing the severity of symptoms.

Wikipedia : 77 Bipolar disorder, previously known as manic depression, is a mental disorder that causes periods of... more...

Sources

Related Diseases for Bipolar Disorder

About this section

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 356)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 33.3 BDNF COMT DISC1 DISC2 DRD3 SLC6A4
2 bipolar i disorder 33.2 BDNF COMT SLC6A4
3 schizoaffective disorder 33.1 BDNF COMT DAOA DISC1 DISC2 DRD3
4 depression 33.1 BDNF DISC2 RELN SLC6A4
5 schizophrenia 33.1 ATP2A2 BDNF COMT DAOA DAOA-AS1 DISC1
6 psychotic disorder 33.1 BDNF COMT DAOA DISC1 DRD3 RELN
7 mood disorder 32.9 BDNF COMT DAOA DISC1 DISC2 DRD3
8 migraine with or without aura 1 32.9 COMT DRD3 SLC6A4
9 schizophrenia 2 32.1 DISC1 DISC2 DRD3
10 anxiety 32.1 BDNF COMT SLC6A4
11 mental depression 32.0 BDNF COMT SLC6A4
12 personality disorder 32.0 BDNF COMT SLC6A4
13 borderline personality disorder 32.0 BDNF COMT SLC6A4
14 attention deficit-hyperactivity disorder 31.8 BDNF COMT DRD3 SLC6A4
15 substance abuse 31.8 BDNF COMT DRD3 SLC6A4
16 obsessive-compulsive disorder 31.8 BDNF COMT DRD3 SLC6A4
17 disease of mental health 31.7 BDNF COMT DISC1 DRD3 RELN SLC6A4
18 alcohol dependence 31.6 BDNF COMT DRD3 SLC6A4
19 eating disorder 31.5 BDNF COMT SLC6A4
20 substance dependence 31.3 BDNF DRD3 SLC6A4
21 post-traumatic stress disorder 31.2 BDNF COMT SLC6A4
22 alcohol abuse 31.2 BDNF DRD3 SLC6A4
23 panic disorder 31.2 COMT DAOA-AS1 SLC6A4
24 paranoid schizophrenia 31.2 BDNF COMT SLC6A4
25 postpartum depression 31.0 BDNF COMT SLC6A4
26 generalized anxiety disorder 31.0 BDNF COMT SLC6A4
27 pervasive developmental disorder 30.9 BDNF RELN SLC6A4
28 tardive dyskinesia 30.9 COMT DRD3
29 autism spectrum disorder 30.9 BDNF DISC2 RELN SLC6A4
30 anorexia nervosa 30.7 BDNF COMT SLC6A4
31 alexithymia 30.6 COMT SLC6A4
32 oppositional defiant disorder 30.5 COMT SLC6A4
33 fibromyalgia 30.5 COMT SLC6A4
34 bulimia nervosa 30.5 BDNF COMT SLC6A4
35 traumatic brain injury 30.5 BDNF COMT
36 parkinson disease, late-onset 30.4 BDNF COMT DRD3 SLC6A4
37 pathological gambling 30.3 DRD3 SLC6A4
38 major affective disorder 3 11.5
39 major affective disorder 4 11.5
40 major affective disorder 8 11.5
41 major affective disorder 7 11.5
42 major affective disorder 9 11.5
43 cyclothymic disorder 11.3
44 major affective disorder 1 11.1
45 major affective disorder 2 11.1
46 major affective disorder 5 11.1
47 major affective disorder 6 11.1
48 valproate embryopathy 11.1
49 darier-white disease 10.9
50 mental retardation, x-linked, syndromic 13 10.9

Comorbidity relations with Bipolar Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypertension, Essential Hypothyroidism
Major Affective Disorder 9 Major Depressive Disorder
Parkinson Disease, Late-Onset Schizophrenia
Schizophreniform Disorder Tardive Dyskinesia

Graphical network of the top 20 diseases related to Bipolar Disorder:



Diseases related to Bipolar Disorder
Sources

Symptoms & Phenotypes for Bipolar Disorder

About this section

GenomeRNAi Phenotypes related to Bipolar Disorder according to GeneCards Suite gene sharing:

27 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.64 IMPA2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.64 IMPA2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.64 DRD3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.64 DRD3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.64 ATP2A2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.64 DRD3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.64 DRD3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.64 DRD3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.64 ATP2A2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.64 ATP2A2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.64 ATP2A2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.64 IMPA2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.64 ATP2A2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.64 ATP2A2 DRD3 IMPA2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.64 ATP2A2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.64 DRD3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.64 DRD3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.64 IMPA2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.64 DRD3
20 Decreased DCP1a protein expression and assembly in processing bodies after arsenite stimulation GR00203-A 9.13 DRD3 RELN SLC6A4
Sources

Drugs & Therapeutics for Bipolar Disorder

About this section

Drugs for Bipolar Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 500)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 106266-06-2 5073
2
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
3
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
4
Topiramate Approved Phase 4,Phase 3,Phase 1 97240-79-4 5284627
5
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
6
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 132539-06-1 4585
7
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
8
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
9
Sertraline Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79617-96-2 68617
10
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
11
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 54910-89-3 3386
12
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 298-46-4 2554
13
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 616-91-1 12035
14
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
15
Coal tar Approved Phase 4,Phase 2 8007-45-2
16
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
17
Bupropion Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 34841-39-9, 34911-55-2 444
18
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 5095 497540
19
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 61869-08-7 43815
20
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
21
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
22
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
23
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6740-88-1 3821
24
Midazolam Approved, Illicit Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable 59467-70-8 4192
25
Pramipexole Approved, Investigational Phase 4,Phase 2 104632-26-0 119570 59868
26
tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1401-55-4
27
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
28
Varenicline Approved, Investigational Phase 4,Not Applicable 249296-44-4 5310966
29
Nortriptyline Approved Phase 4 72-69-5 4543
30
Modafinil Approved, Investigational Phase 4,Phase 2 68693-11-8 4236
31
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 65576-45-6, 85650-56-2 3001386
32
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
33
Iloperidone Approved Phase 4,Phase 1 133454-47-4 71360
34
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-36-2 446220 5760
35
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 16590-41-3 5360515
36
Galantamine Approved Phase 4,Phase 3,Not Applicable 357-70-0 9651
37
Clozapine Approved Phase 4,Phase 3,Phase 2,Not Applicable 5786-21-0 2818
38
Ondansetron Approved Phase 4,Phase 3 99614-02-5 4595
39
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
40
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
41
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 51-45-6 774
42
Tranylcypromine Approved, Investigational Phase 4,Not Applicable 155-09-9 441233
43
Acetylcholine Approved, Investigational Phase 4,Not Applicable 51-84-3 187
44
Acamprosate Approved, Investigational Phase 4,Phase 1,Phase 2 77337-76-9 71158
45
Cycloserine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 68-41-7 401 6234
46
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
47
Donepezil Approved Phase 4 120014-06-4 3152
48
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 10118-90-8 5281021
49
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
50
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-53-3 2726

Interventional clinical trials:

(show top 50) (show all 1325)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
2 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
3 Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
4 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
5 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
6 Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder Unknown status NCT02252341 Phase 4
7 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
8 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
9 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
10 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
11 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
12 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
13 Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
14 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
15 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
16 Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
17 Targeting Cognition in Bipolar Disorder With Pramipexole Completed NCT02397837 Phase 4 Pramipexole;Placebo
18 Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder Completed NCT00667745 Phase 4 Lithium Carbonate;Optimized Treatment (OPT)
19 Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder Completed NCT01010204 Phase 4 Varenicline;Placebo
20 Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder Completed NCT02456896 Phase 4 Oxcarbazepine
21 Memantine and Cognitive Dysfunction in Bipolar Disorder Completed NCT00586066 Phase 4 Memantine;Placebo
22 Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode Completed NCT02918097 Phase 4 Lithium Carbonate;Sertraline;Nortriptyline;Risperidone
23 Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder Completed NCT01864551 Phase 4 Lamotrigine;Olanzapine
24 Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil Completed NCT01965925 Phase 4 Modafinil;Placebo
25 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States. Completed NCT00154323 Phase 4 Oxcarbazepine
26 Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine Completed NCT00394095 Phase 4 Topiramate;Placebo
27 Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder Completed NCT00199966 Phase 4 Divalproex sodium extended release
28 Comparative Effectiveness Study for Bipolar Disorder Completed NCT01331304 Phase 4 Lithium;Quetiapine
29 Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
30 Aripiprazole in Late Life Bipolar Disorder Completed NCT00194038 Phase 4 Aripiprazole
31 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
32 Asenapine in the Treatment of Older Adults With Bipolar Disorder Completed NCT01460290 Phase 4 Asenapine
33 Ziprasidone in Pediatric Bipolar Disorder Completed NCT00622739 Phase 4 Ziprasidone;Ziprasidone
34 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
35 Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad) Completed NCT01293825 Phase 4 ziprasidone
36 Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder Completed NCT01195363 Phase 4 quetiapine SR;quetiapine sr placebo
37 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
38 Iloperidone in Mixed States of Bipolar Disorder Completed NCT02413918 Phase 4 iloperidone
39 Cognitive Enhancement in Bipolar Disorder Completed NCT00597896 Phase 4 pramipexole
40 An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder Completed NCT00360126 Phase 4 lamotrigine
41 Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder Completed NCT00552760 Phase 4 Ramelteon;Placebo
42 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4 Lamotrigine;Placebo
43 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
44 Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder Completed NCT00741598 Phase 4 Galantamine-ER;Galantamine placebo
45 Lamictal As Add on Treatment in Mixed States of Bipolar Disorder Completed NCT00223509 Phase 4 Lamotrigine
46 FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder Completed NCT00596622 Phase 4 Lithium
47 Geodon in Weight Loss Study for Bipolar Disorders Completed NCT00472641 Phase 4 Ziprasidone/Geodon
48 Valproic Acid Sodium Salt in Bipolar Disorder Completed NCT00431522 Phase 4 Valproic acid, sodium salt
49 Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Completed NCT00845988 Phase 4 aripiprazole
50 Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder? Completed NCT00571688 Phase 4 Risperdal (risperidone) Consta;Treatment as usual

Search NIH Clinical Center for Bipolar Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: bipolar disorder

Sources

Genetic Tests for Bipolar Disorder

About this section
Sources

Anatomical Context for Bipolar Disorder

About this section

MalaCards organs/tissues related to Bipolar Disorder:

42
Brain, Cortex, Testes, Eye, Heart, Amygdala, Prefrontal Cortex
Sources

Publications for Bipolar Disorder

About this section

Articles related to Bipolar Disorder:

(show top 50) (show all 5515)
# Title Authors Year
1
Alexithymia predicts poorer social and everyday functioning in schizophrenia and bipolar disorder. ( 30658205 )
2019
2
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. ( 29855563 )
2019
3
An evaluation of the impact of co-occurring anxiety and substance use disorder on bipolar disorder illness outcomes in STEP-BD. ( 30623826 )
2019
4
The Association of Lifetime Suicide Attempts With Anxiety Disorders in Patients With Bipolar Disorder. ( 30633727 )
2019
5
Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. ( 30292023 )
2019
6
The impact of COMT polymorphisms on cognition in Bipolar Disorder: A review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. ( 30146088 )
2019
7
The impact of BDNF Val66Met polymorphism on cognition in Bipolar Disorder: A review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. ( 30078664 )
2019
8
MRI features of clinical outcome in bipolar disorder: A selected review: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. ( 29907266 )
2019
9
Risks of bipolar disorder, depressive disorder, and traumatic brain injury among siblings of patients with attention-deficit hyperactivity disorder. ( 30419534 )
2019
10
Attention deficit-hyperactivity disorder in adult bipolar disorder patients. ( 30267955 )
2019
11
Impulsivity and its association with childhood trauma experiences across bipolar disorder, attention deficit hyperactivity disorder and borderline personality disorder. ( 30336349 )
2019
12
Sexually Transmitted Infection Among Adolescents and Young Adults With Bipolar Disorder: A Nationwide Longitudinal Study. ( 30901168 )
2019
13
Discussion on Patients with Bipolar Disorder and Depressive Episode by Ratio Low Frequency Amplitude Combined with Grey Matter Volume Analysis. ( 30905048 )
2019
14
Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines. ( 30905116 )
2019
15
Gender-related differences in patients with bipolar disorder: a nationwide study. ( 30905327 )
2019
16
Bipolar disorder and the college student: A review and implications for universities. ( 30908152 )
2019
17
Disease-only alleles at the extreme ends of the human ZMYM3 exceptionally long 5' UTR short tandem repeat in bipolar disorder: A pilot study. ( 30909162 )
2019
18
Quantitative separation of the depressive phase of Bipolar Disorder and Major Depressive Disorder using Electrovestibulography. ( 30912461 )
2019
19
Risk factors for early unplanned readmission in patients with bipolar disorder: A retrospective observational study. ( 30913417 )
2019
20
Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy. ( 30915592 )
2019
21
'What people diagnosed with bipolar disorder experience as distressing': A meta-synthesis of qualitative research. ( 30731279 )
2019
22
Study of 45 candidate genes suggests CACNG2 may be associated with lithium response in bipolar disorder. ( 30738251 )
2019
23
Cortical thickness and surface area as an endophenotype in bipolar disorder type I patients and their first-degree relatives. ( 30738374 )
2019
24
Genetic and environmental influences on circulating NK and T cells and their relation to bipolar disorder. ( 30739250 )
2019
25
Improving functional outcomes in early-stage bipolar disorder: The protocol for the REsearch into COgnitive and behavioural VERsatility trial. ( 30740882 )
2019
26
Tamoxifen for bipolar disorder: Systematic review and meta-analysis. ( 30741085 )
2019
27
Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review. ( 30743017 )
2019
28
Variation in the CACNB2 gene is associated with functional connectivity of the Hippocampus in bipolar disorder. ( 30744588 )
2019
29
Corrigendum to "Identifying cognitive subgroups in bipolar disorder: A cluster analysis" [Journal of Affective Disorders 246C (2019) 252-261]. ( 30745154 )
2019
30
Identification of factors affecting treatment outcome in bipolar disorder. ( 30745650 )
2019
31
Obsessive-compulsive disorder comorbid with schizophrenia and bipolar disorder. ( 30745688 )
2019
32
Living the life you want following a diagnosis of bipolar disorder: A grounded theory approach. ( 30746808 )
2019
33
Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia. ( 30747428 )
2019
34
Baseline and follow-up activity and functional connectivity in reward neural circuitries in offspring at risk for bipolar disorder. ( 30755725 )
2019
35
Targeting the immune system in the treatment of bipolar disorder. ( 30756134 )
2019
36
The role of pre-, peri-, and postnatal risk factors in bipolar disorder and adult ADHD. ( 30758784 )
2019
37
Association of functioning and quality of life with objective and subjective measures of sleep and biological rhythms in major depressive and bipolar disorder. ( 30759998 )
2019
38
Mapping of modifiable barriers and facilitators of medication adherence in bipolar disorder to the Theoretical Domains Framework: a systematic review protocol. ( 30760516 )
2019
39
Elevated Familial Cardiovascular Burden Among Adolescents With Familial Bipolar Disorder. ( 30761021 )
2019
40
High concentrations of serum interleukin-6 and interleukin-8 in patients with bipolar disorder. ( 30762747 )
2019
41
Spanish validation of the Barcelona TEMPS-A questionnaire in patients with bipolar disorder and general population. ( 30772748 )
2019
42
Distinct temporal brain dynamics in bipolar disorder and schizophrenia during emotion regulation. ( 30773147 )
2019
43
The use of component-wise gradient boosting to assess the possible role of cognitive measures as markers of vulnerability to pediatric bipolar disorder. ( 30774035 )
2019
44
The Link between Thyroid Autoimmunity, Depression and Bipolar Disorder. ( 30775452 )
2019
45
Fine-mapping scan of bipolar disorder susceptibility loci in Latino pedigrees. ( 30779416 )
2019
46
Salivary melatonin onset in youth at familial risk for bipolar disorder. ( 30780062 )
2019
47
A case of methamphetamine use disorder presenting a condition of ultra-rapid cycler bipolar disorder. ( 30783527 )
2019
48
Effective care for Māori with bipolar disorder: A qualitative study. ( 30784163 )
2019
49
Bipolar disorder and bone health: A systematic review. ( 30784723 )
2019
50
Network dynamics of positive and negative affect in bipolar disorder. ( 30784724 )
2019
Sources

Variations for Bipolar Disorder

About this section

Copy number variations for Bipolar Disorder from CNVD:

7 (show top 50) (show all 399)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13918 1 100964950 101093664 Deletion Bipolar disorder
2 13959 1 101777242 101789688 Copy number Bipolar disorder
3 14276 1 106411328 106634702 Copy number Bipolar disorder
4 15012 1 111824223 111936532 Deletion Bipolar disorder
5 15144 1 112987422 113369070 Deletion Bipolar disorder
6 15198 1 113388739 114043773 Deletion Bipolar disorder
7 15265 1 114105331 114260861 Deletion Bipolar disorder
8 15293 1 114379103 114611497 Deletion Bipolar disorder
9 15315 1 114627212 115118807 Deletion Bipolar disorder
10 17285 1 142400000 148000000 Deletion Bipolar disorder
11 17371 1 142600000 147000000 Copy number Bipolar disorder
12 17555 1 14341488 14762438 Deletion Bipolar disorder
13 18108 1 144093481 144503421 Deletion Bipolar disorder
14 21577 1 159722810 159884140 Copy number FCGR2A Bipolar disorder
15 21578 1 159722810 159884140 Copy number FCGR2C Bipolar disorder
16 21579 1 159722810 159884140 Copy number FCGR3A Bipolar disorder
17 21580 1 159722810 159884140 Copy number FCGR3B Bipolar disorder
18 21581 1 159722810 159884140 Copy number HSPA6 Bipolar disorder
19 24355 1 179082079 179207535 Deletion Bipolar disorder
20 27840 1 214001144 214182688 Deletion Bipolar disorder
21 30012 1 239069843 239226340 Deletion Bipolar disorder
22 30852 1 246404335 246667943 Deletion Bipolar disorder
23 30991 1 247034191 247138092 Deletion Bipolar disorder
24 31736 1 30336050 30952188 Deletion Bipolar disorder
25 34240 1 53925291 53984359 Copy number GLIS1 Bipolar disorder
26 35075 1 59854502 60323099 Deletion Bipolar disorder
27 35289 1 62052182 62289893 Deletion Bipolar disorder
28 35722 1 66557267 66646247 Copy number PDE4B Bipolar disorder
29 35951 1 696962 803181 Deletion Bipolar disorder
30 37047 1 84784450 84864145 Copy number CTBS Bipolar disorder
31 37048 1 84784450 84864145 Copy number SPATA1 Bipolar disorder
32 37147 1 85996510 86164671 Deletion Bipolar disorder
33 38265 10 10058972 10215130 Deletion Bipolar disorder
34 39159 10 111195021 111323778 Deletion Bipolar disorder
35 39762 10 119100000 135374737 Deletion Bipolar disorder
36 40469 10 128361479 128559816 Deletion Bipolar disorder
37 42381 10 32899498 33000799 Deletion Bipolar disorder
38 42648 10 37554667 37710375 Deletion Bipolar disorder
39 43112 10 44523027 44679489 Copy number Bipolar disorder
40 43587 10 47013328 47173619 Copy number Bipolar disorder
41 44374 10 56148428 56359760 Deletion Bipolar disorder
42 47196 10 90344868 90556337 Deletion Bipolar disorder
43 47223 10 90559662 90957411 Deletion Bipolar disorder
44 49063 11 102652001 102778728 Deletion Bipolar disorder
45 50159 11 114721884 114868905 Deletion Bipolar disorder
46 51811 11 131159857 131261275 Deletion Bipolar disorder
47 51869 11 132518807 132864395 Deletion Bipolar disorder
48 51963 11 133786141 134449982 Deletion Bipolar disorder
49 53165 11 25250128 26084796 Deletion Bipolar disorder
50 53245 11 26949271 27197653 Deletion Bipolar disorder
Sources

Expression for Bipolar Disorder

About this section
Search GEO for disease gene expression data for Bipolar Disorder.
Sources

Pathways for Bipolar Disorder

About this section

Pathways related to Bipolar Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neurotransmitter Clearance In The Synaptic Cleft 67
Show member pathways
 10.04 COMT SLC6A4
Sources

GO Terms for Bipolar Disorder

About this section

Biological processes related to Bipolar Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphate-containing compound metabolic process GO:0006796 9.37 IMPA1 IMPA2
2 response to pain GO:0048265 9.32 COMT RELN
3 dopamine metabolic process GO:0042417 9.26 COMT DRD3
4 inositol phosphate dephosphorylation GO:0046855 9.16 IMPA1 IMPA2
5 learning GO:0007612 9.13 COMT DRD3 RELN
6 inositol biosynthetic process GO:0006021 8.62 IMPA1 IMPA2

Molecular functions related to Bipolar Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inositol monophosphate 1-phosphatase activity GO:0008934 9.26 IMPA1 IMPA2
2 inositol monophosphate 3-phosphatase activity GO:0052832 9.16 IMPA1 IMPA2
3 inositol monophosphate 4-phosphatase activity GO:0052833 8.96 IMPA1 IMPA2
4 inositol monophosphate phosphatase activity GO:0052834 8.62 IMPA1 IMPA2
Sources

Sources for Bipolar Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....